A Phase 2 interventional study of Fingolimod 0.5mg/daily and Placebo in Acute Demylelinating Optic Neuritis, sponsored by Novartis Pharmaceuticals. Terminated at 2 sites in 2 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2015-05-04.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Optic Neuritis with a site in United States — 5 open to participants now, 7 under way, 2 of them phase 3. Optic Neuritis · United States.
Among the 29 studies in Optic Neuritis with a site in United States, this one is the 18th largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2013, is one of 4 in phase 2, and was the 13th registered.
88 studies on the registry are indexed under Optic Neuritis; 16 are open to participants now.
Browse Optic Neuritis studies →5 of the 29 studies in Optic Neuritis with a site in United States are open now. Recruiting first, the newest first:
Oculis · Sites in United States
Ages 18–50
Anastasia Vishnevetsky, MD, MPH · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul · Sites in United States, Argentina, Australia and 14 more countries
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Optic Neuritis studies recruiting now, 7 (50%) set no upper age limit and 6 (43%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 9 · Phase 4 3
First in 1988; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 50 across 58 interventional studies indexed under Optic Neuritis.
Median enrollment 43 across the 20 interventional studies, 131 across the 6 observational. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 1 study filed under Optic Neuritis — fewer than ten, so there is no comparison to draw.
1 of the studies in Optic Neuritis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06453694Anastasia Vishnevetsky, MD, MPHEfgartigimod for the Treatment of Acute Optic Neuritis | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Optic Neuritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of fingolimod 0.5mg versus placebo in patients with suspected acute demyelinating optic neuritis (ADON) receiving standard steroid treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women of who are not using highly effective method of
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral capsule dose was given once daily for 48 weeks
Drug: Fingolimod 0.5mg/daily
Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48
Drug: Placebo
Drug page: Fingolimod
Also known as: FTY, Gilenya
Mean Retinal Nerve Fiber Layer (RNFL) Thinning in Patients Treated With Fingolimod 0.5mg/Day, Relative to Patients Treated With Placebo
Due to early termination and low patient enrollment the primary outcome measure was not analyzed
Time frame: Baseline and Week 18
Low Contrast Visual Acuity (LCVA)
Due to early termination and low patient enrollment this trial was not powered for efficacy
Time frame: Baseline, Week 48
Vision Based Quality of Life (QoL) Utility Score
Due to early termination and low patient enrollment this trial was not powered for efficacy
Time frame: Baseline, Week 18, Week 48
Proportion of Paatients Converting to Either 2005 or 2010 McDonald MS or to CDMS
Due to early termination and low patient enrollment this trial was not powered for efficacy
Time frame: Baseline, Week 18, Week 48
Number of Particpants With Adverse Events as a Measure of Safety and Tolerability
Number of particpants with Adverse events as a measure of safety and tolerability
Time frame: Weeks 0, 4, 8, 12, 18, 24, 36, 48, 60
| Milestone | Fingolimod 0.5mg/Daily | Placebo |
|---|---|---|
| Started | 2 | 0 |
| Completed | 0 | 0 |
| Not completed | 2 | 0 |
| Withdrew: Administrative problems | 2 | 0 |
Due to early termination and low patient enrollment the primary outcome measure was not analyzed
No measurements were reported for this outcome.
Due to early termination and low patient enrollment this trial was not powered for efficacy
No measurements were reported for this outcome.
Due to early termination and low patient enrollment this trial was not powered for efficacy
No measurements were reported for this outcome.
Due to early termination and low patient enrollment this trial was not powered for efficacy
No measurements were reported for this outcome.
Number of particpants with Adverse events as a measure of safety and tolerability
| Participants | Fingolimod 0.5mg/Daily |
|---|---|
| Adverse Events (AE) | 1 |
| Death | 0 |
| Non -Fatal Seriuos Aderse Event (SAE) | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fingolimod 0.5mg/Daily | — | 0/2 (0%) | 1/2 (50%) |
| Placebo | — | — | — |
| Event | Fingolimod 0.5mg/Daily | Placebo |
|---|---|---|
| VomitingGastrointestinal disorders | 1/2 | — |
| NasopharyngitisInfections and infestations | 1/2 | — |
| ASTHMA EXACERBATIONRespiratory, thoracic and mediastinal disorders | 1/2 | — |
| Age, Categorical(Participants) | Fingolimod 0.5mg/Daily |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 2 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Fingolimod 0.5mg/Daily |
|---|---|
| Female | 2 |
| Male | 0 |
The record gives a start of Aug 2013, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in May 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod